SCHEMBL8937333

SCHEMBL8937333

CCOc1ccc(/C(=C/C(=O)O)c2cc(Cl)cc(Cl)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.48
PARP10 Q53GL7 1/20 0.46
CSNK2A2 P19784 1/20 0.46
CSNK2B P67870 1/20 0.46
CSNK2A1 P68400 1/20 0.46
CSNK2A3 Q8NEV1 1/20 0.46
PLA2G4B P0C869 1/20 0.46
NPC1 O15118 2/20 0.44
PLK1 P53350 1/20 0.44
MAOA P21397 1/20 0.44
NPSR1 Q6W5P4 3/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937340 1.00 MAOB (0.48) MAOBPARP10CSNK2A2CSNK2BCSNK2A1
SCHEMBL8937336 1.00 MAOB (0.48) MAOBPARP10CSNK2A2CSNK2BCSNK2A1
SCHEMBL8937387 0.92 MAOB (0.44) MAOBPARP10CSNK2A2CSNK2BCSNK2A1
SCHEMBL8937391 0.92 MAOB (0.44) MAOBPARP10CSNK2A2CSNK2BCSNK2A1
SCHEMBL8937383 0.92 MAOB (0.44) MAOBPARP10CSNK2A2CSNK2BCSNK2A1
SCHEMBL8937361 0.84 HPGD (0.50) MAOBPARP10MAOANPSR1ALDH1A1
SCHEMBL8937315 0.84 HPGD (0.50) MAOBPARP10MAOANPSR1ALDH1A1
SCHEMBL8937358 0.84 HPGD (0.50) MAOBPARP10MAOANPSR1ALDH1A1
SCHEMBL8937226 0.81 GAA (0.54) NPC1PLK1LMNAMAPK1ALDH1A1
SCHEMBL8937228 0.81 GAA (0.54) NPC1PLK1LMNAMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed